Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

AstraZeneca1,236 enrolled

Overview

Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.

Study Type

OBSERVATIONAL

Enrollment

1,236

Conditions

Hypercholesterolemia Cardiovascular Disease Hypertension Diabetes Coronary Heart Disease Peripheral Arterial Disease

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subject must provide informed consent and comply with the survey procedures. * Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. Exclusion Criteria: \- Subjects who are unwilling or unable to provide informed consent.

Outcomes

Primary Outcomes

Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.

Time frame: 24 weeks

Secondary Outcomes

Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.

In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients

Time frame: 24 weeks

Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines

Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven

Time frame: 24 weeks

Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.

For the following sub-populations: Demographic variables, CV risk factors \& Lipid-lowering agent class

Time frame: 24 weeks

The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.